TXNIP and metabolic dysfunction-associated steatotic liver disease: Treatment with salidroside improves dyslipidemia and inhibits hepatic lipid deposition and attenuates NAFLD by modulating oxidative stress and inhibiting the TXNIP/NLRP3 pathway [73].